Methods of treating ocular diseases
A method of treating a complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof, in a subject in need thereof, the method comprising of administering to the subject a therapeutically effective amount of an antibody which inhibits the alternative complement pathway, wherein the antibody administered is effective for inhibiting complement mediated ocular inflammation, hemorrhaging and fibrosis, and the pathological consequences thereof.
1. A method of treating ocular pathologies associated with fibrosis and hemorrhage within and around the macula of a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of an anti-C3b antibody or antigen binding fragment thereof that binds to a component of alternative pathway and inhibits alternative pathway activation, wherein the ant-C3b antibody or antigen binding fragment thereof includes a light chain variable domain including 3CDRs of SEQ ID NO: 39 and a heavy chain variable domain including 3CDRs of SEQ ID NO: 82.
2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof inhibits alternative complement pathway activation without inhibiting classical pathway activation.
3. The method of claim 1 , wherein the antibody or antigen binding fragment thereof binds to C3b.
4. The method of any of claim 3 , wherein the antibody or antigen binding fragment thereof neutralizes the component of the alternative pathway function.
5. The method of claim 1 , wherein the antibody or antigen binding fragment thereof binds to a complement regulator that controls complement activation.
6. The method of claim 1 , wherein the antibody or antigen binding fragment thereof selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.
7. The method of claim 1 , wherein the antibody or antigen binding fragment thereof selectively inhibits formation of PC3bBb produced by the alternative pathway.
8. The method of claim 1 , wherein the antibody or antigen binding fragment thereof binds to C3b.
9. The method of claim 1 , wherein the therapeutically effective amount of antibody or antigen binding fragment thereof is an amount effective for comprehensive treatment of macular degeneration, geographic atrophy and retinal fibrosis.
10. The method of claim 1 , wherein the subject has dry age-related macular degeneration and the therapeutically effective amount of antibody or antigen binding fragment thereof is an amount of antibody effective to treat the dry age-related macular degeneration.
11. The method of claim 1 , wherein the subject has wet age-related macular degeneration and the therapeutically effective amount of antibody or antigen binding fragment thereof is an amount of anti-properdin antibody effective to treat the wet age-related macular degeneration.
12. The method of claim 1 , wherein the subject has geographic atrophy and the therapeutically effective amount of antibody or antigen binding fragment thereof is an amount of antibody or antigen binding fragment thereof effective to treat the geographic atrophy.
13. The method of claim 1 , wherein the subject has geographic atrophy post onset of wet age-related macular degeneration and the therapeutically effective amount of antibody or antigen binding fragment thereof is an amount of antibody or antigen binding fragment thereof effective to treat the geographic atrophy.
14. The method of claim 1 , wherein the subject has geographic atrophy post onset of dry age-related macular degeneration and the therapeutically effective amount of antibody or antigen binding fragment thereof is an amount of antibody or antigen binding fragment thereof effective to treat the geographic atrophy.
15. The method of claim 1 , wherein the subject has early-stage age-related macular degeneration or excessive drusen pre-age-related macular degeneration and the therapeutically effective amount of antibody or antigen binding fragment thereof is an amount of antibody or antigen binding fragment thereof effective to inhibit onset of age-related macular degeneration.
16. A method of treating ocular disorders in a subject in need thereof, comprising administering to the subject undergoing anti-VEGF, anti-PDGF treatment a therapeutically effective amount of an anti-C3b antibody or antigen binding fragment thereof that binds to a component of alternative pathway and inhibits alternative pathway activation, wherein the anti-C3b antibody or antigen binding fragment thereof includes a light chain variable domain including 3CDRs of SEQ ID NO: 39 and a heavy chain variable domain including 3CDRs of SEQ ID NO: 82.
17. The method of claim 16 , wherein the antibody or antigen binding fragment thereof has a reduced effector function.
18. The method of claim 16 , wherein the antibody is a hybrid of two antibody isoforms.
19. The method of claim 16 , wherein the antibody or antigen binding fragment thereof binds to a component of alternative pathway C3 convertase and inhibits alternative pathway activation.
20. The method of claim 16 , wherein the antibody or antigen binding fragment thereof selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced by the alternative pathway but not the classical pathway.